Skip to main content

Table 1 Patient data before and after Glargine therapy

From: Diabetes outbreak during COVID19 lock-down in a prediabetic patient with cystic fibrosis long treated with glargine

  Age (years) Lumacaftor Ivacaftor BMI
z-score
FEV1 (%) Annual number of pulmonary exacerbations Annual number of pulmonary exacerbations treated by intravenous antibiotics
2016 (before Glargine therapy) 13.1 NO −1.58 90.4% 7 4
2017 (1 year of Glargine therapy) 14.5 NO −1.54 91% 4 2
2018 (2 years of Glargine therapy) 15.7 YES −1.47 75% 2 0
2019 (3 years of Glargine therapy) 16.3 YES −1.78 74% 3 0
2020 (COVID-19 pandemic lockdown) 17.0 YES −2.47 68% 4 0
2020 (November) 17.6 YES −1.58 71% 4 0